so that s the one side. and regarding the us, your other question, well, we have good relations with the us and always had. we are probably not 100% transatlantic, as some expect us to be. we try to.act like bismarck did. he tried to have good relations, interest relations, that you need not be friends with. countries are never friends, they only have interests. and, yes, we have interests in the us, but we also have interests elsewhere, and we are trying to be.equal distance to all of them and try to have some sort of relation. and the same holds, of course, with the us as well. but, yes, at the same time, we can be critical towards the us in some respects. but personally, i see the us as very important. mr boehringer, sadly, we re out of time, but i do thank you very much for joining me on hardtalk. thank you. thank you, stephen.
Zealand Pharma and partner Boehringer Ingelheim said their experimental obesity drug achieved up to 14.9% weight loss after 46 weeks in a mid-stage trial, adding a potential contestant to the fast. | May 10, 2023
Phase II dose-finding trial met primary endpoint after 46 weeks of treatment, representing an important advancement of Boehringer Ingelheim's cardio-renal-metabolic focus areas Full data will
Boehringer Ingelheim announced today that it has launched clinical development of its first-in-class IL-11 inhibitor antibody BI 765423 with a Phase 1 study (NCT05658107) to assess the safety, tolerability